Showing results (151-160 of 177) with videos related to

Sort By:
Pageof 18
Urologic Oncology|June 11, 2021
Impact of health-related quality of life on repeat protocol biopsy compliance on active surveillance for favorable prostate cancer: results from a prospective cohort in the PRIAS-JAPAN studyYoichiro Tohi, Takuma Kato, Akira Yokomizo, et al.
Japanese Journal of Clinical Oncology|March 1, 2022
Olaparib in patients with mCRPC with homologous recombination repair gene alterations: PROfound Asian subset analysisNobuaki Matsubara, Kazuo Nishimura, Satoru Kawakami, et al.
European Urology Open Science|January 13, 2022
Prostate Cancer Patients Under Active Surveillance with a Suspicious Magnetic Resonance Imaging Finding Are at Increased Risk of Needing Treatment: Results of the Movember Foundation's Global Action Plan Prostate Cancer Active Surveillance (GAP3) ConsortiumJonathan Olivier, Weiyu Li, Daan Nieboer, et al.
International Journal of Clinical Oncology|August 10, 2020
The impact of complications after initial prostate biopsy on repeat protocol biopsy acceptance rate. Results from the Prostate Cancer Research International: Active Surveillance JAPAN studyYoichiro Tohi, Takuma Kato, Ryuji Matsumoto, et al.
European Urology|January 22, 2026
Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 TrialHiroshi Kitamura, Taiji Tsukamoto, Yoshiyuki Kakehi, et al.
Plos One|December 9, 2016
Development of RNA-FISH Assay for Detection of Oncogenic FGFR3-TACC3 Fusion Genes in FFPE SamplesMasahiro Kurobe, Takahiro Kojima, Kouichi Nishimura, et al.
The Lancet. Oncology|September 15, 2023
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trialFred Saad, Noel W Clarke, Mototsugu Oya, et al.
International Journal of Clinical Oncology|February 28, 2024
Peripheral neuropathy and nerve electrophysiological changes with enfortumab vedotin in patients with advanced urothelial carcinoma: a prospective multicenter cohort studyRikiya Taoka, Masaki Kamada, Kazuyoshi Izumi, et al.
Japanese Journal of Clinical Oncology|June 6, 2022
Impact of adherence to criteria on oncological outcomes of radical prostatectomy in patients opting for active surveillance: data from the PRIAS-JAPAN studyYoichiro Tohi, Takuma Kato, Jimpei Miyakawa, et al.
Cancer Science|March 18, 2025
Olaparib Plus Abiraterone in Asian Patients With Metastatic Castration-Resistant Prostate Cancer: PROpel Subset AnalysisMototsugu Oya, Jae Young Joung, Ji Youl Lee, et al.
Pageof 18